Simufilam dihydrochloride NEW
| Price | $44 | $92 | $146 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: Simufilam dihydrochloride | CAS No.: 2480226-06-8 |
| Purity: 98.83% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | Simufilam dihydrochloride |
| Description | Simufilam dihydrochloride (PTI-125 dihydrochloride) is a low toxicity, orally active filamin A (FLNA) activator, which can be used for the research of Alzheimer's disease. Simufilam dihydrochloride preferentially binds altered FLNA and restores its native conformation, restoring receptor and synaptic activities and reducing its α7nAChR/TLR4 associations and downstream pathologies. |
| In vitro | Simufilam dihydrochloride (1 pM~1 nM) increases NMDA/glycine-induced Arc expression in a dose-dependent manner. Simufilam dihydrochloride (1 nM, 1 hour) largely restores filamin A to its native conformation and effectively normalizes receptor activities in AD frontal cortices. Simufilam dihydrochloride dose-dependently reduces Ab42-induced FLNA coupling to a7nAChR and TLR4 in both Ab42-treated control and AD hippocampus. Simufilam dihydrochloride reduces Ab42's binding affinity for a7nAChR, thereby prevents Ab42's signaling and further accumulation on a7nAChRs. |
| In vivo | Simufilam dihydrochloride (22 mg/kg; p.o.) robustly reduces FLNAea7nAChR/TLR4 associations. Simufilam dihydrochloride significantly improves spatial memory. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 65 mg/mL (195.61 mM), Sonication is recommended. |
| Keywords | Simufilam dihydrochloride | Simufilam | PTI-125 Dihydrochloride | PTI125 Dihydrochloride | PTI-125 | PTI125 | PTI 125 Dihydrochloride | PTI 125 | Inhibitor | inhibit | a7nAChR |
| Inhibitors Related | Flubendazole | Indole-2-carboxylic acid | Urethane | Decanoic Acid | L-Glutamic acid | HEPPS | Adenine | Mitotane | Methylene Blue trihydrate | Methyl eugenol | N,N-Dicyclohexylcarbodiimide | Arecoline |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Anti-Alzheimer's Disease Compound Library | Membrane Protein-targeted Compound Library | Drug Repurposing Compound Library | NO PAINS Compound Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $360.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-04-22 | |
| $1.00 |
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-07-07 | |
| $339.00 |
VIP6Y
|
Shanghai UCHEM Inc.
|
2026-07-08 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY